Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer

Lung Cancer. 2006 Dec;54(3):431-2. doi: 10.1016/j.lungcan.2006.08.008. Epub 2006 Sep 26.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Carboplatin / administration & dosage
  • Carcinoma, Small Cell / drug therapy*
  • Female
  • Humans
  • Irinotecan
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Thalidomide / administration & dosage
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Thalidomide
  • Irinotecan
  • Carboplatin
  • Camptothecin